Please use this identifier to cite or link to this item: http://repo.knmu.edu.ua/handle/123456789/33041
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBilovol, O.-
dc.contributor.authorKniazkova, I.-
dc.contributor.authorKirienko, O.-
dc.contributor.authorKuzminova, N.-
dc.contributor.authorSushetska, A.-
dc.contributor.authorStarenkiy, V.-
dc.contributor.authorAbramova, L.-
dc.date.accessioned2023-11-23T14:54:55Z-
dc.date.available2023-11-23T14:54:55Z-
dc.date.issued2023-
dc.identifier.citationDynamics of SST2 and NT-PROBNP in patients with arterial hypertension and type 2 diabetes mellitus based on combined therapy with eplerenone and trimetazidine addition / O. M. Bilovol, I. I. Kniazkova, O. M. Kirienko, N. V. Kuzminova, A. S. Sushetska, V. P. Starenkiy, L. P. Abramova // World of Medicine and Biology. – 2023. – № 1 (83). – P. 21–25.en_US
dc.identifier.urihttp://repo.knmu.edu.ua/handle/123456789/33041-
dc.description.abstractThe purpose of our study was to investigate the effect of complex therapy with the addition of eplerenone and trimetazidine on the state of left ventricular diastolic function, as well as levels of soluble growth-stimulatingreceptor expressed by gene 2 and N-terminal fragment of brain natriuretic propeptide in patients with arterial hypertension with type 2 diabetes mellitus. After registration baseline data were recorded, 42 patients (group 1) were prescribed baseline therapy and 38 patients (group 2) were prescribed eplerenone 25-50 mg once daily and trimetazidine 80 mg once daily in addition to antihypertensive therapy for 3 months. The control group consisted of 20 practically healthy individuals. After the treatment, a significant decrease in the level of soluble growth-stimulatingreceptor expressed by gene 2 in the blood of patients in both groups was found, but in group 2 this indicator did not differ from the control group, while in group 1 it remained significantly higher than in healthy individuals. At the same time, the level of N-terminal fragment of brain natriuretic propeptide significantly decreased by 1.3 times and 1.6 times in groups 1 and 2, respectively, but remained significantly higher than in the control group. A significant decrease E/e`mean was determined in both groups of patients, but in group 2 by 8.9 % less than in group 2 and a decrease in the geometric parameters of the left atrium, more pronounced in group 2. Thus, the addition of eplerenone and trimetazidine to the complex therapy of patients with arterial hypertension and type 2 diabetes mellitus during 3 months improved diastolic function, and also had a positive effect on the biomarker of myocardial stress and fibrosis soluble growth-stimulatingreceptor expressed by gene 2 level and myocardial dysfunction N-terminal fragment of brain natriuretic propeptide concentration in serumen_US
dc.language.isoenen_US
dc.subjectsoluble growth-stimulatingreceptor expressed by gene 2, N-terminal fragment of brain natriuretic propeptideen_US
dc.subjectN-terminal fragment of brain natriuretic propeptideen_US
dc.subjecttype 2 diabetes mellitusen_US
dc.subjecteplerenoneen_US
dc.subjectdiastolic functionen_US
dc.subjectarterial hypertensionen_US
dc.subjectTrimetazidineen_US
dc.subject2023аen_US
dc.titleDynamics of SST2 and NT-PROBNP in patients with arterial hypertension and type 2 diabetes mellitus based on combined therapy with eplerenone and trimetazidine additionen_US
dc.typeArticleen_US
Appears in Collections:Наукові праці. Кафедра клінічної фармакології та внутрішньої медицини

Files in This Item:
File Description SizeFormat 
Bilovol_Dynamics of SST2 and NT-PROBNP in patients with arterial hypertension and.pdf428,01 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.